Key takeaways for Utah
- • Zepbound is the FIRST and ONLY FDA-approved drug for OSA (Dec 2024).
- • Approved only for moderate-to-severe OSA in adults with obesity.
- • AHI reductions of 25-30 events/hour in the SURMOUNT-OSA trials.
- • Utah Medicaid coverage rules apply for Obstructive Sleep Apnea patients in Utah — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Obstructive Sleep Apnea
Zepbound is FDA-approved (Dec 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. Evidence grade: A. In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index (AHI) by roughly 25-30 events per hour at 52 weeks, with a substantial fraction of patients reaching disease remission. CPAP remains standard of care — Zepbound is positioned as adjunct or alternative for patients who cannot tolerate CPAP. Other GLP-1s (Wegovy, semaglutide) are not approved for OSA but may produce indirect benefit via weight loss.
Utah-specific context
Utah has telehealth access concentrated in Salt Lake City, West Valley City, West Jordan metros, with additional reach to Provo and Sandy. University of Utah Health, Intermountain Healthcare is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at medicaid.utah.gov.
Utahtelehealth & pricing rules
- • Utah permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Utah allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Utah: ~$268/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.